Marathon Partners Equity Management is urging Dr. Martens to undergo a strategic review, including a potential sale of the company, to maximize shareholder value. The share price of the British bootmaker is down sharply since it was floated on the London Stock Exchange in January 2021.
Your membership benefits:
If you aren’t ready to subscribe now, choose the 30 day trial for 1€. To continue reading this article REGISTER NOW.